Day: June 15, 2023

Infant Bacterial Therapeutics AB (IBT) announces today that the European Patent Office has approved its patent application for Lactobacillus reuteri. The patent pertains to the drug candidate IBP-9414, currently undergoing Phase III development by IBT for the prevention of Necrotizing Entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants. The invention encompasses a unique method of activating freeze-dried bacteria. The patent reinforces the existing protection for IBT’s drug candidate IBP-9414, which has been granted both orphan drug status and data exclusivity for biological products in the USA and EU. The patent is valid until 2036, providing IBT with long-term protection and competitive advantages. The plan is to launch IBP-9414 in the European market as soon as market authorization is obtained. CEO Staffan...

Original Cookie Cake Franchise Now Open in Anchorage LOS ANGELES, June 15, 2023 (GLOBE NEWSWIRE) — Great American Cookies, the Original Cookie Cake franchise, announces its first location in the state of Alaska. Located in Anchorage, the new store serves as the ultimate sweet spot for locals with desserts including Custom Cookie Cakes, fresh, soft-baked cookies, brownies, and more. “This year, Great American Cookies arrived in Arizona, New Mexico, and Illinois,” said Allison Lauenstein, President of Great American Cookies. “Growing domestically has been a key growth pillar for us so we are pleased to be able to expand our footprint to four new states, including Alaska, in just a few months. We see Anchorage as a great market to make our Alaska debut in, providing a perfect spot for family nights, birthdays, and beyond.” Since...

Presentation Includes Data on All 33 CAR T-Naïve Patients Treated with the Alloy™ Manufactured Material and Recaps Data on 12 Large B Cell Lymphoma Patients Treated with Phase 2 Dose Regimen Results Indicate an Off-the-Shelf Allogeneic CAR T Can Potentially Deliver Durable Complete Responses Comparable to Autologous CAR T Therapies Potentially Pivotal Phase 2 ALPHA2 Trials Ongoing in the U.S.; Sites in Europe, Canada and Australia Expected to Enroll During 2023SOUTH SAN FRANCISCO, Calif., June 15, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland presented updated data from the Phase 1 ALPHA/ALPHA2...

Patents Strengthen Sunrise’s Intellectual Property Portfolio, Paving the Way for Future Expansion ZIBO, China, June 15, 2023 (GLOBE NEWSWIRE) — Sunrise New Energy Co., Ltd. (“Sunrise New Energy”, the “Company”, “we” or “our”) (NASDAQ: EPOW), today announced that the China National Intellectual Property Administration (CNIPA) has granted the Company five patents, marking significant advancements in the field of silicon anode manufacturing. These patents reinforce the Company’s commitment to innovation and position it at the forefront of next-generation lithium-ion battery technology. The granted patents include: AJ220008f-1B Sunrise (Guizhou) New Energy Materials Co. 2017111552502: A lithium-ion battery, silicon carbon cathode material used and its preparation method. AJ220018f-1 Sunrise (Guizhou) New Energy Materials...

Kuala Lumpur, Malaysia, June 15, 2023 (GLOBE NEWSWIRE) — Kairous Acquisition Corp. Limited (NASDAQ: KACL, the “Company”), a special purpose acquisition company, announced today that Kairous Asia Limited, the Company’s initial public offering sponsor (“Sponsor”), has deposited into the Company’s trust account (the “Trust Account”) an aggregate of $120,000, in order to extend the period of time the Company has to complete a business combination for an additional one (1) month period, from June 16, 2023 to July 16, 2023. The Company issued a promissory note to Sponsor with a principal amount equal to the amount deposited. The promissory note bears no interest and will be converted into the Company’s ordinary shares at a price of $10.10 per share at the closing of a business combination by the Company. The purpose of the extension...